Cannabis Science, Inc. is a development-stage company involved in medical marijuana research and development. The company is committed to creating medicines—both with and without psychoactive properties—that are cannabis-based. These medicines aim to treat both the disease and its symptoms, and are also for general health maintenance. Cannabis Science, Inc. is the first and only publicly traded biotech company in the market that is involved in cannabinoid-based extracts, and trades in the OTC market under the symbol CBIS.
To put it simply, the company’s products are medical cannabinoid formulations that stem from at least one of the cannabinoid compounds of the cannabis plant with a primary focus of treating cancer—one of the most important diseases across the globe.
Formerly known as Gulf Onshore, Inc., Cannabis Science is among the oldest companies in the cannabis industry. From the very beginning, its founders have been dedicated to their cause of nurturing and upholding a spirit that encourages innovation from which novel ideas develop and turn into solutions based on evidence.
Thanks to its unique understanding of metabolic processes, the patent-oriented biotech company aims to provide alternative treatment options for individuals with medical needs that are unmet. The company utilizes an inquiring approach in order to discover and develop therapies that can improve patients’ lives.
Cannabis Science continues to create these products with medical cannabinoid formulations as part of its commitment to advocate for the rights of those dealing with life-threatening and debilitating conditions. It works closely with regulatory agencies on local, national, and international levels to ensure the accessibility of their high-quality cannabinoid pharmaceuticals.
Cannabis Science, Inc. works closely with leading experts in clinical research, drug development, and medicinal characterization to develop, create, and commercialize new therapeutic approaches that treat an extensive number of critical ailments such as infections, cancer, and age-related illnesses. All of the materials used in Cannabis Science’s clinical trial are from cultivation and production facilities that are GMP compliant, and that exceed industry standards and food processing requirements.
Yahoo! Finance: CBIS News
Latest Financial News for CBIS
A new collaborative institute aims to study cannabis as part of its mission to increase access to evidence-based plant medicine in poor and developing nations. The International Phytomedicines Institute (IPI) at Harvard Medical School, was launched on May 26 during the 2019 Global Health Catalyst summit at Harvard Medical School, an annual conference focused primarily on reducing disparities to access to healthcare.
IRVINE, CA, July 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that Mr. Raymond C. Dabney (RCD), Founder and CEO of Cannabis Science, Inc. (CBIS), is completing a negotiated majority control acquisition of another U.S. public company.
To look at Cannabis One Holdings Inc. is to view a bloodied stock chart squashed by investors who took a sumo-wrestler like short position aiming break the company.
IRVINE, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the appointment of Dr. Sulma Mohammed, Professor of Cancer Biology at Purdue University, to the Company’s Scientific Advisory Board. Dr. Mohammed has extensive knowledge of molecular biology, cell biology, biochemistry, and microbiology, basic and applied medical sciences through her graduate programs at Cornell University and Purdue University, as well as experience in cancer research from the basic levels, to pre-clinical research in animal models, through to human clinical trials.
IRVINE, CA, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the research and development of cannabinoid-based medicines, is proud to announce it has been introduced as one of the key industry partners in the recently launched, ground-breaking International Phytomedicines Institute (IPI) at Harvard Medical School. The International Phytomedicines Institute (IPI), launched during this year’s Harvard GHC Summit, is a transformative initiative by the Global Health Catalyst designed to elevate phytomedicines in global health, accelerate clinical translation and commercialization of evidence-based plant medicines/healthcare products and provide a world class core facility for research, and consultation on medicinal plants.